In contrast, blood from MS patients do not display as robust a type I IFN signature as SLE or T1D patients, and many studies have demonstrated that IFNβ treatment has therapeutic properties in animal models of MS and in affected individuals. Here, IFNB1 is linked to systemic lupus erythematosus.